NEW YORK, Dec. 5, 2010 /PRNewswire/ -- See video from Roche Pharmaceuticals at:
Roche announced positive data from a Phase III study of Rituxan/MabThera (rituximab) in patients with advanced follicular lymphoma who did not have symptoms of disease (asymptomatic disease). Phase III study showed Rituxan/MabThera for initial use followed by continued use delayed need for additional therapy in people with asymptomatic follicular lymphoma, a common type of blood cancer. Rituxan/MabThera decreased the risk of needing later treatment with chemotherapy or radiotherapy by 80%. Available video includes mode of action, animations, product shots as well as soundbites.
thenewsmarket.com delivers free broadcast- and streaming-quality video and multimedia content directly to media around the world, 24/7. More than 25,000 media outlets in 190+ countries use thenewsmarket.com, including the AP, BBC, CNBC, CNN, France 24, N24, nytimes.com, RAI, TVE, ZDF and a lot more.
Registered journalists can preview and download video, audio, text, graphics and photos at http://www.thenewsmarket.com.
If not already registered, please take a moment to sign up - registration is quick, easy and free: http://www.thenewsmarket.com/registration
We are always happy to receive your feedback, suggestions or enquiries. Email us at firstname.lastname@example.org
Story Id: 20726